) R F! N1 i* _; o* T# H
临床上有依维莫司联合EGFR TKI作为易/特耐药之后的方案的研究:# D" h2 A3 n3 W; q
Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer. + B+ g' o) q0 h; Y, rhttp://www.ncbi.nlm.nih.gov/pubmed/22968184( S9 q* d V# R0 t* C. z